CPN Trials

  • Open and Active
    • MAY2013-02-01 "Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection"
    • MAY2013-02-02 "Pilot Study of EGFR Inhibition with Erlotinib in Cirrhosis to Inhibit Fibrogenesis and Prevent Hepatocellular Carcinoma"
    • MAY2015-05-01 "Randomized, Double-blind, Placebo-controlled Trial of Meriva (curcumin) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis"
  • In Development
    • MAY2016-07-01 "Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated with Familial Adenomatous Polyposis"
    • MAY2016-08-01 "A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer"
    • MAY2017-09-01 "Phase I Randomized Trial of 300 µg Delayed-Release (DR) Linaclotide versus Placebo to Demonstrate Colorectal Bioactivity in Healthy Volunteers"
  • Closed/Completed
    • MAY2013-01-01 "Randomized, Double-blind, Placebo-controlled Trial of MUC1 Vaccine in Patients with Newly Diagnosed Advanced Adenoma"
    • MAY2012-00-01 "Dose De-Escalation/Escalation Trial to Identify the Lowest Commercially Available Dose of Linaclotide that Maintains Bioactivity in Rectal Mucosa." This manuscript is in press.
    • MAY06-8-01 "Phase IIb Trial of Myo-inositol in Smokers with Bronchial Dysplasia." This manuscript has been accepted for publication and will be available soon.
    • MAY10-15-02 "Pioglitazone as a Candidate Chemoprevention Agent for Lung Cancer: A Pilot Trial Using a Pre-Surgical Model in Early Stage NSCLC." This manuscript is in preparation.
    • MAY10-15-03 "Randomized Double Blind Placebo Controlled Phase II Trial of Barrett's Esophagus Chemoprevention with Metformin." Review the published manuscript.
    • CPN0935 "Feasibility Study to Assess Interest for Chemoprevention Trial Participation Among BRCA Mutation Carriers." Review the published manuscript.
    • CPN0942 "Pilot Study of MHC Class I Protein Expresson in FAP-Associated Dysplastic and Histologically-Normal Gastrointestinal Tissue Specimens." This manuscript is in preparation.
    • CPN1033 "BRCA Gene Mutation Carrier Versus Normal Breast Tissue: Biomarkers of Breast Cancer Risk"
    • CPN1341 "15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus as a Correlate of Response to Aspirin Therapy"
    • CPN1343 "Genomic Responsiveness to Aspirin"
    • CPN1342 "Methylated NTRK3 and Colorectal Cancer Formation"
    • CPN1441 "The Role of Gastrin in Proliferation and Apoptosis in Nondysplastic Human Barrett's Esophagus"
    • CPN1442 "Metformin and mitochondrial homeostasis in Barrett's esophagus"
    • MAY03-1-02 "Randomized Phase IIb Trial of Sulindac in Smokers With Bronchial Dysplasia."
    • Review the published MAY03-1-02 manuscript.
    • MAY04-4-01 "Randomized, Double-Blinded Phase II Trial of Esomeprazole Versus Esomeprazole Plus Two Doses of Aspirin in Barrett's Esophagus Patients."
    • Review the published MAY04-4-01 manuscript.
    • MAY07-9-01 "Single-Dose Phase 0 Exploratory Pharmacokinetic Clinical Trial Comparing Five Oral Formulations of SR13668, an Orally Active AKT Pathway Inhibitor."
    • Review the published MAY07-9-01 manuscript.
    • CPN1191 "Population-Based Pharmacokinetic Analyses of data from the Bioequivalency Study of Sulindac in Capsule vs. Tablet Formulations."
    • Review the published CPN1191 manuscript.
    • MAY03-1-03 "Randomized Phase II Trial of Atorvastatin, Raftilose Synergy 1, and Sulindac Among Patients at Increased Risk for Sporadic Colorectal Neoplasia."
    • Review the published MAY03-1-03 manuscript.
    • MAY03-1-BIO "Bioequivalency Study of Sulindac in Capsule vs. Tablet Formulations."
    • Review the published MAY03-1-BIO manuscript.